Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Mayo Clinic
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
Hoffmann-La Roche
City of Hope Medical Center
Aveni Foundation
MacroGenics
City of Hope Medical Center
Ocellaris Pharma, Inc.
Eli Lilly and Company
UNICANCER
Memorial Sloan Kettering Cancer Center
Tanabe Pharma America, Inc.
Bristol-Myers Squibb
Transgene
HiFiBiO Therapeutics
Stella Pharma Corporation
TScan Therapeutics, Inc.
Bayer
M.D. Anderson Cancer Center
Actym Therapeutics, Inc.
Hadassah Medical Organization
Novartis
Travera Inc
Valo Therapeutics Oy
Epkin
Institut Bergonié
Turning Point Therapeutics, Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
NextPoint Therapeutics, Inc.
Stanford University
Sarcoma Oncology Research Center, LLC
BostonGene
Agenus Inc.
Stanford University
Cybrexa Therapeutics
Agenus Inc.
Taiho Pharmaceutical Co., Ltd.
NantCell, Inc.
National Cancer Institute (NCI)
Xencor, Inc.
Innolake Biopharm
Pfizer
National Cancer Institute (NCI)
BioEclipse Therapeutics
Adaptimmune
Corvus Pharmaceuticals, Inc.